Abstract:Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that drive Eph receptor signalling, and investigates the contribution of intra- and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6. Throughout this review, we carefully analyse and reconcile the existing/conflicting data in the field, to allow researchers to further the current understanding of Eph receptor signalling.

Cross-Linking of EphB6 Resulting in Signal Transduction and Apoptosis in Jurkat Cells

Structures of an Eph receptor tyrosine kinase and its potential activation mechanism.

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

Identification of Interaction Partners for Individual SH3 Domains of Fas Ligand Associated Members of the PCH Protein Family in T Lymphocytes.

Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.

Ephrinb1 Is Essential In T-Cell-T-Cell Co-Operation During T-Cell Activation

Mouse Ephrinb3 Augments T-Cell Signaling And Responses To T-Cell Receptor Ligation

Ephrin B2 Induces T Cell Costimulation

Ephrin-B1 is Critical in T-cell Development*

Neutrophil CD16b Crosslinking Induces Lipid Raft-Mediated Activation of SHP-2 and Affects Cytokine Expression and Retarded Neutrophil Apoptosis

Co-clustering of EphB6 and ephrinB1 in trans restrains cancer cell invasion

Eph receptor signalling: from catalytic to non-catalytic functions

Determining The Effects Of Ephrin Type-B Receptor 6 And Type-A Receptor 3 On Facilitating Colorectal Epithelial Cell Malignant Transformation

Physical interaction with Ephrin B1 promotes CXCR4 intracellular localization and oncogenic potential

Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly

Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses

Contrasting Effects of Cancer-Associated Mutations in EphA3 and EphB2 Kinases

LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis

High-Expressed CXCR7 Contributes to CXCL12-Mediated Protection from Apoptosis in Lymphoma Cells

Eph receptor tyrosine kinase and its relation to cancer

High Expression of EphB6 Protein in Tongue Squamous Cell Carcinoma is Associated with a Poor Outcome.